Amolyt Pharma Announces Two Presentations, Including Phase 2a Data for AZP-3601 in Patients with Hypoparathyroidism, at the American Society for Bone
Amolyt Pharma Announces Two Presentations, Including Phase 2a Data for AZP-3601 in Patients with Hypoparathyroidism, at the American Society for Bone and Mineral Research 2022 Annual MeetingCompany to host Key Opinion Leader webinar on September 12 at 2:00 pm CT/3:00 pm ETLYON, France and CAMBRIDGE, Mass., Sept. 01,...
Source: pharmiweb.com